Royal Bank of Canada’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-35,076
| Closed | -$707K | – | 8217 |
|
|
2021
Q3 | $707K | Sell |
35,076
-6,864
| -16% | -$190K | ﹤0.01% | 4025 |
|
|
2021
Q2 | $1.57M | Buy |
41,940
+1,168
| +3% | +$35.8K | ﹤0.01% | 3274 |
|
|
2021
Q1 | $1.04M | Buy |
40,772
+40,657
| +35,354% | +$1.04M | ﹤0.01% | 3543 |
|
|
2020
Q4 | $3K | Sell |
115
-919
| -89% | -$20.2K | ﹤0.01% | 6834 |
|
|
2020
Q3 | $19K | Sell |
1,034
-200
| -16% | -$4.14K | ﹤0.01% | 5726 |
|
|
2020
Q2 | $31K | Buy |
1,234
+955
| +342% | +$20.6K | ﹤0.01% | 5425 |
|
|
2020
Q1 | $6K | Sell |
279
-2,356
| -89% | -$45.8K | ﹤0.01% | 6009 |
|
|
2019
Q4 | $58K | Buy |
+2,635
| New | +$53K | ﹤0.01% | 5388 |
|
|
2018
Q4 | – | Sell |
-1,192
| Closed | -$18K | – | 7331 |
|
|
2018
Q3 | $18K | Buy |
1,192
+1,039
| +679% | +$15.1K | ﹤0.01% | 5748 |
|
|
2018
Q2 | $2K | Buy |
+153
| New | +$1.92K | ﹤0.01% | 6292 |
|
|
2018
Q1 | – | Sell |
-1,016
| Closed | -$9K | – | 6991 |
|
|
2017
Q4 | $9K | Buy |
1,016
+1,007
| +11,189% | +$7.41K | ﹤0.01% | 5920 |
|
|
2017
Q3 | $0 | Buy |
+9
| New | +$33 | ﹤0.01% | 7112 |
|
|
2016
Q1 | – | Sell |
-22
| Closed | – | – | 6770 |
|
|
2015
Q4 | $0 | Sell |
22
-700
| -97% | -$8.01K | ﹤0.01% | 6915 |
|
|
2015
Q3 | $6K | Sell |
722
-248
| -26% | -$2.86K | ﹤0.01% | 6115 |
|
|
2015
Q2 | $14K | Buy |
+970
| New | +$17.8K | ﹤0.01% | 5908 |
|
|
2015
Q1 | – | Sell |
-2
| Closed | – | – | 6496 |
|
|
2014
Q4 | $0 | Buy |
+2
| New | +$23 | ﹤0.01% | 6357 |
|
Other funds holding DRNA
Royal Bank of Canada's DRNA Position: Q4 2021 in Review
Royal Bank of Canada sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q4 2021, closing a stake of 35,076 shares — an estimated $707K sold.
Royal Bank of Canada first reported a position in DRNA in Q4 2014 and held it in 16 quarters. The position peaked at $1.57M in Q2 2021. 1 fund tracked by Wall St. Rank holds DRNA as of Q4 2021.
- Royal Bank of Canada reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
- Royal Bank of Canada sold 35,076 Dicerna Pharmaceuticals, Inc. shares in Q4 2021, an estimated $707K.
- Royal Bank of Canada first reported a position in Dicerna Pharmaceuticals, Inc. in Q4 2014 and held it in 16 quarters.
- Royal Bank of Canada's Dicerna Pharmaceuticals, Inc. position peaked at $1.57M in Q2 2021.
- 1 fund tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2021.
Based on Royal Bank of Canada's 13F filing for Q4 2021, filed 14 Feb 2022.